781 resultados para asymptotic weight
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
The age and growth of Mugil cephalus was investigated in Bonny Estuary, Nigeria, from January, 1995 to December, 1996. Length-weight relationships were isometric with length exponents of 2.84 (males), 2.90 (females) and 2.88 (overall). Modal length at age were 12.0cm, 20.9cm, 25.0cm, 28.4cm and 30.2cm TL for ages 0+, 1+, 2+, 3+ and 4+ respectively. Corresponding total weights were 20.01g, 78.93g, 173.12g, 217.61g and 247.50g, respectively. Asymptotic length (Lo) was estimated 33.2cm TL, asymptotic weight (W sub(o)) was 484g, growth coefficient K=0.55847 super(-1) and hypothetical age at zero length To = 0.152yr. Longevity, Tmax, was 5.0yr, length and weight growth performance indices were Q super(1)=2.79 and Q = 1.44, respectively. Total mortality, natural mortality and fishing mortality were z = 1.02yr super(-1), M=0.607yr super(-1) and F=O. 3129yr super(-1), respectively. The exploitation ratio E was 0.4048 and exploitation rate U = 0.2302yr super(-1)
Resumo:
The Dhir Beel, one of the major live beels of the Brahmaputra Basin, Assam, has an area of 689 ha and situated in Dhubri district of Assam. The dominance of freshwater shark, Wallago attu (8.10%) in the beel is a striking feature. Restricted breeding of W. attu once a year from June to September was observed. The mean observed length was 37.5, 65.0, 84.5 and 99.0 cm in the 6th, 12th, 18th and 24th months of age respectively. The length growth coefficient (K), the asymptotic length (L infinity ), and the arbitrary origin of the growth curve (t omicron ), for W. attu were estimated to be 0.054484 per month, 136.16 cm and 0.0355 month respectively. The calculated life span (T infinity ) of the fish is 123.86 months (about 10 years). The weight growth parameters were estimated where the monthly growth coefficient (K), the asymptotic weight (W infinity) and the arbitrary origin of the growth curve (t omicron) were found to be 0.0743 per month, 7636.92 gram and 0.431908 month respectively. The length-weight relationship follows the cube law.
Resumo:
Size-spectrum theory is used to show that (i) predation mortality is a decreasing function of individual size and proportional to the consumption rate of predators; (ii) adult natural mortality M is proportional to the von Bertalanffy growth constant K; and (iii) productivity rate P/B is proportional to the asymptotic weight W8 -1/3. The constants of proportionality are specified using individual level parameters related to physiology or prey encounter. The derivations demonstrate how traditional fisheries theory can be connected to community ecology. Implications for the use of models for ecosystem-based fisheries management are discussed.
Resumo:
We propose mo deIs to analyze animal growlh data wilh lhe aim of eslimating and predicting quanlities of Liological and economical interest such as the maturing rate and asymptotic weight. lt is also studied lhe effect of environmenlal facLors of relevant influence in the growlh processo The models considered in this paper are based on an extension and specialization of the dynamic hierarchical model (Gamerman " Migon, 1993) lo a non-Iinear growlh curve sdLillg, where some of the growth curve parameters are considered cxchangeable among lhe unils. The inferencc for thcse models are appruximale conjugale analysis Lascd on Taylor series cxpallsiulIs aliei linear Bayes procedures.
Resumo:
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Resumo:
Objetivou-se estimar parâmetros genéticos, utilizando inferência Bayesiana, para as estimativas dos parâmetros individuais de peso à maturidade (Â) e taxa de crescimento, obtidos pela função de crescimento Brody. O arquivo estava constituído de 14.563 registros de pesos e idades referentes a 1.158 fêmeas da raça Nelore, participantes do Programa de Melhoramento Genético da Raça Nelore. Para a análise das estimativas dos parâmetros da curva, via inferência bayesiana, foi proposto um modelo animal unicaráter, que incluiu como fixo o efeito de grupo contemporâneo (animais nascidos no mesmo estado, no mesmo trimestre do ano, mesmo ano e mesmo regime alimentar) e como aleatórios os efeitos genético direto e residual. Nessa análise, foram utilizados dois diferentes tamanhos para as cadeias geradas pelo algoritmo de amostragem de Gibbs, de 550 e 1.100 mil ciclos, com períodos de descarte amostral de 50 e 100 mil ciclos, respectivamente, e amostragens a cada 500 e 1.000 ciclos, respectivamente. As médias posteriores da variância genética aditiva e residual foram próximas, tanto para  quanto para a, mesmo quando implementados diferentes tamanhos para as cadeias geradas pelo algoritmo de amostragem de Gibbs. Os coeficientes de herdabilidade estimados para Â, variaram de 0,44 a 0,46, amplitude semelhante aos 0,46 a 0,48 obtidos para as estimativas de. Essas magnitudes indicam que a seleção pode ser usada como instrumento para alterar a forma da curva de crescimento desses animais. Entretanto, o uso das informações obtidas, visando à alteração da curva de crescimento dos animais, deve ser feito com grande cautela, uma vez que as características a serem trabalhadas na modificação do formato da curva de crescimento, de acordo com resultados da literatura especializada, são negativamente correlacionadas.
Resumo:
Com o objetivo de ajustar modelos não-lineares, foram utilizados registros mensais do peso de 10 fêmeas de cateto (Pecari tajacu) coletados durante dois anos, no criatório do campo experimental Álvaro Adolfo da Embrapa Amazônia Oriental, Belém, PA. Utilizaram-se os modelos de Von Bertalanffy, Brody, Gompertz e Logístico. Os parâmetros foram estimados usando o procedimento NLIN do aplicativo SAS. Os critérios utilizados para verificar o ajuste dos modelos foram: desvio padrão assintótico (ASD); coeficiente de determinação (R2); desvio médio absoluto dos resíduos (ARD) e o índice assintótico (AR). Os modelos Brody e Logístico estimaram, respectivamente, o maior (19,44kg) e o menor (19,18kg) peso assintótico (A), caracterizando a menor (0,0064kg/dia) e a maior (0,0113kg/dia) taxa de maturação (K), haja vista a natureza antagônica entre estes parâmetros, comprovada pela correlação fenotípica variando entre -0,75 à -0,47. O modelo Brody estimou o menor valor para o ARD, fator limitante para caracterizar o menor valor para o AR por este modelo. Considerando o AR, o modelo Brody apresentou o melhor ajuste, contudo, pelos valores encontrados, os demais modelos também apresentaram ajuste adequando aos dados ponderais da referida espécie/sexo. Com base no AR adotado neste trabalho, recomenda-se o modelo Brody para ajustar a curva de crescimento de fêmeas de cateto (Pecari tajacu). Em razão dos valores estimados, sobretudo, para a K, essa característica pode ser incluída em um índice de seleção. Contudo, estudos com grupos mais representativos e criados em outras condições se faz oportuno.
Resumo:
In two experiments, we show that the beliefs women have about the controllability of their weight (i.e., weight locus of control) influences their responses to advertisements featuring a larger-sized female model or a slim female model. Further, we examine self-referencing as a mechanism for these effects. Specifically, people who believe they can control their weight (“internals”), respond most favorably to slim models in advertising, and this favorable response is mediated by self-referencing. In contrast, people who feel powerless about their weight (“externals”), self-reference larger-sized models, but only prefer larger-sized models when the advertisement is for a non-fattening product. For fattening products, they exhibit a similar preference for larger-sized models and slim models. Together, these experiments shed light on the effect of model body size and the role of weight locus of control in influencing consumer attitudes.
Resumo:
Introduction: Weight gain is a common concern following breast cancer and has been associated with negative health outcomes. As such, prevention of weight gain is of clinical interest. This work describes weight change between 6- and 18-months following a breast cancer diagnosis and explores the personal, treatment and behavioural characteristics associated with gains in weight. Methods: Body mass index was objectively assessed, at three-monthly intervals, on a population-based sample of women newly diagnosed with unilateral breast cancer (n=185). Changes in BMI between 6- and 18-months post-diagnosis were calculated, with gains of one or more being considered clinically detrimental to future health. Results: Approximately 60% of participants were overweight or obese at 6-months post-diagnosis. While BMI remained relatively stable across the testing period (range=27.3-27.8), 24% of participants experienced clinically relevant gains in BMI (median gains=1.9). Following adjustment for potential confounders, younger age (<45 years; Odds ratio, OR=9.8), being morbidly obese at baseline (OR=4.6) and receiving hormone therapy (OR=4.8) were characteristics associated with an increased odds (p<0.05) of gaining BMI. Other characteristics associated with gains in BMI were more extensive surgery and having a history of smoking, although these relationships were not supported statistically. In contrast, caring for younger children was associated with reduced risk of gaining BMI (OR=0.3, p=0.20). Conclusions: Clinically relevant weight gain between 6- and 18-months post-breast cancer diagnosis is an issue for one in four women, with certain subgroups being particularly susceptible. However, the majority of women diagnosed with breast cancer are overweight or obese and gains in body weight are common. Thus, interventions that address the importance of achieving and sustaining a healthy body weight, delivered to all women with breast cancer, may have greater public health impact than interventions targeting any specific breast cancer subgroup.
Resumo:
Background: Exercise is widely promoted as a method of weight management, while the other health benefits are often ignored. The purpose of this study was to examine whether exercise-induced improvements in health are influenced by changes in body weight. Methods: Fifty-eight sedentary overweight/obese men and women (BMI 31.8 (SD 4.5) kg/m2) participated in a 12-week supervised aerobic exercise intervention (70% heart rate max, five times a week, 500 kcal per session). Body composition, anthropometric parameters, aerobic capacity, blood pressure and acute psychological response to exercise were measured at weeks 0 and 12. Results: The mean reduction in body weight was −3.3 (3.63) kg (p<0.01). However, 26 of the 58 participants failed to attain the predicted weight loss estimated from individuals’ exercise-induced energy expenditure. Their mean weight loss was only −0.9 (1.8) kg (p<0.01). Despite attaining a lower-than-predicted weight reduction, these individuals experienced significant increases in aerobic capacity (6.3 (6.0) ml/kg/min; p<0.01), and a decreased systolic (−6.00 (11.5) mm Hg; p<0.05) and diastolic blood pressure (−3.9 (5.8) mm Hg; p<0.01), waist circumference (−3.7 (2.7) cm; p<0.01) and resting heart rate (−4.8 (8.9) bpm, p<0.001). In addition, these individuals experienced an acute exercise-induced increase in positive mood. Conclusions: These data demonstrate that significant and meaningful health benefits can be achieved even in the presence of lower-than-expected exercise-induced weight loss. A less successful reduction in body weight does not undermine the beneficial effects of aerobic exercise. From a public health perspective, exercise should be encouraged and the emphasis on weight loss reduced.
Resumo:
Objective: In the majority of exercise intervention studies, the aggregate reported weight loss is often small. The efficacy of exercise as a weight loss tool remains in question. The aim of the present study was to investigate the variability in appetite and body weight when participants engaged in a supervised and monitored exercise programme. ---------- Design: Fifty-eight obese men and women (BMI = 31·8 ± 4·5 kg/m2) were prescribed exercise to expend approximately 2092 kJ (500 kcal) per session, five times a week at an intensity of 70 % maximum heart rate for 12 weeks under supervised conditions in the research unit. Body weight and composition, total daily energy intake and various health markers were measured at weeks 0, 4, 8 and 12. ---------- Results: Mean reduction in body weight (3·2 ± 1·98 kg) was significant (P < 0·001); however, there was large individual variability (−14·7 to +2·7 kg). This large variability could be largely attributed to the differences in energy intake over the 12-week intervention. Those participants who failed to lose meaningful weight increased their food intake and reduced intake of fruits and vegetables. ---------- Conclusion: These data have demonstrated that even when exercise energy expenditure is high, a healthy diet is still required for weight loss to occur in many people.
Resumo:
Background: The incidence of obesity is increasing; this is of major concern, as obesity is associated with cardiovascular disease, stroke, type 2 diabetes, respiratory tract disease, and cancer. Objectives/methods: This evaluation is of a Phase II clinical trial with tesofensine in obese subjects. Results: After 26 weeks, tesofensine caused a significant weight loss, and may have a higher maximal ability to reduce weight than the presently available anti-obesity agents. However, tesofensine also increased blood pressure and heart rate, and may increase psychiatric disorders. Conclusions: It is encouraging that tesofensine 0.5 mg may cause almost double the weight loss observed with sibutramine or rimonabant. As tesofensine and sibutramine have similar pharmacological profiles, it would be of interest to compare the weight loss with tesofensine in a head-to-head clinical trial with sibutramine, to properly assess their comparative potency. Also, as teso fensine 0.5 mg increases heart rate, as well as increasing the incidence of adverse effects such as nausea, drug mouth, flatulence, insomnia, and depressed mode, its tolerability needs to be further evaluated in large Phase III clinical trials.